Related Experiment Videos
Antipyrine absorption after delayed oesophageal capsule transit
British Journal of Clinical Pharmacology
|August 1, 1984
Summary
When a capsule disintegrates in the esophagus, it significantly reduces antipyrine absorption and delays its peak plasma concentration. This delayed gastric transit impacts the drug's overall pharmacokinetic profile.
Area of Science:
- Pharmacology
- Gastroenterology
- Drug Delivery
Background:
- Oral drug administration relies on successful transit through the gastrointestinal tract.
- Capsule formulations can sometimes encounter transit issues, particularly in the esophagus.
- Understanding the impact of esophageal capsule impaction on drug absorption is crucial for optimizing oral therapies.
Purpose of the Study:
- To investigate the pharmacokinetic consequences of delayed capsule transit in the esophagus.
- To compare antipyrine absorption and plasma concentration profiles when capsules successfully reach the stomach versus disintegrate in the esophagus.
Main Methods:
- Twenty fasted patients received hard gelatin capsules containing antipyrine and barium.
- Plasma antipyrine levels were measured at regular intervals over 4 hours.
- Pharmacokinetic parameters were analyzed, comparing patients with rapid gastric entry versus esophageal impaction.
Main Results:
- Esophageal disintegration significantly reduced first-hour antipyrine absorption (P < 0.0005).
- Peak plasma concentration was delayed by an average of 46 minutes (P < 0.01).
- Peak plasma concentrations were significantly lower in cases of esophageal impaction (P < 0.05).
Conclusions:
- Delayed capsule transit through the esophagus significantly alters the pharmacokinetic profile of orally administered antipyrine.
- Esophageal capsule impaction leads to reduced drug absorption and delayed systemic availability.
- These findings highlight the importance of successful esophageal transit for effective oral drug delivery.